Volitionrx (VNRX) Current Deferred Revenue (2021 - 2025)
Volitionrx filings provide 5 years of Current Deferred Revenue readings, the most recent being $353846.0 for Q4 2025.
- On a quarterly basis, Current Deferred Revenue rose 53.85% to $353846.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $353846.0, a 53.85% increase, with the full-year FY2025 number at $353846.0, up 53.85% from a year prior.
- Current Deferred Revenue hit $353846.0 in Q4 2025 for Volitionrx, roughly flat from $354000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $12.5 billion in Q4 2021 to a low of $101097.0 in Q2 2024.
- Median Current Deferred Revenue over the past 5 years was $5.2 million (2022), compared with a mean of $788.1 million.
- The widest YoY moves for Current Deferred Revenue: up 19447.79% in 2024, down 99.0% in 2024.
- Volitionrx's Current Deferred Revenue stood at $12.5 billion in 2021, then crashed by 99.92% to $10.0 million in 2022, then soared by 130.0% to $23.0 million in 2023, then plummeted by 99.0% to $230000.0 in 2024, then surged by 53.85% to $353846.0 in 2025.
- The last three reported values for Current Deferred Revenue were $353846.0 (Q4 2025), $354000.0 (Q3 2025), and $122441.0 (Q2 2025) per Business Quant data.